Use of 5‐alpha reductase inhibitors and risk of gastrointestinal cancers in men with benign prostatic hyperplasia: A population‐based cohort study

Documenti analoghi

• Dutasteride, a 5 alpha reductase inhibitor, could be associated with the exacerbation of inflammation in patients with benign prostatic hyperplasia
  di: So Inamura, et al.
  Pubblicazione: (2024)
• Determinants of active surveillance uptake in a diverse population‐based cohort of men with low‐risk prostate cancer: The Treatment Options in Prostate Cancer Study (TOPCS)
  di: Jinping Xu, et al.
  Pubblicazione: (2024)
• Factors associated with switching from active surveillance to treatment in men with low‐risk prostate cancer: A population‐based study
  di: Kevin B. Ginsburg, et al.
  Pubblicazione: (2025)
• Polygenic risk score and prostate specific antigen predict death from prostate cancer in men with intermediate aggressive cancer
  di: Leandro Rodrigues Santiago, et al.
  Pubblicazione: (2025)
• Editorial comment on “Dutasteride, a 5 alpha‐reductase inhibitor, could be associated with the exacerbation of inflammation in patients with benign prostatic hyperplasia”
  di: Tomoaki Tanaka, et al.
  Pubblicazione: (2025)